Literature DB >> 20471452

Neuroprotective effects of Epigallocatechin-3-gallate (EGCG) in optic nerve crush model in rats.

Jun Xie1, Libin Jiang, Ting Zhang, Yulan Jin, Dongmei Yang, Fei Chen.   

Abstract

Epigallocatechin-3-gallate (EGCG), the major catechin found in green tea, is a powerful antioxidant and has anti-inflammatory with neuroprotective potential. This study aims to investigate the neuroprotective effects of EGCG in an optic nerve crush (ONC) model in rats. Seventy-two Wistar rats were randomly divided into four groups: normal control (group A), sham operation+EGCG (group B), ONC+vehicle (group C), and ONC+EGCG (group D). The rats were treated intraperitoneally and orally with either vehicle or EGCG (25 mg/kg, injected daily for 5 days and 2 mg/kg orally daily afterwards). Two days after the first injection, an ONC injury was performed by using a micro optic nerve clipper with 40 g power at approximately 2 mm from the optic nerve head for 60 s. Fluorogold was injected into the bilateral superior colliculi 5 days before sacrifice and fluorescent gold-labelled retinal ganglion cells (RGCs) were counted under fluorescence microscopy on days 7, 14 and 28 after ONC. The expression of Neurofilament triplet L (NF-L) was measured via immunohistochemical and Western blotting analysis. In group C, a progressive loss of RGCs was observed after ONC. In contrast, the density of RGCs was significantly higher in group D (p=0.009, independent samples t-test) on day 7 after ONC, and statistical differences were obtained on days 14 and 28 (p=0.026 and p=0.019, respectively, independent samples t-test). The results of immunohistochemical and Western blotting analysis showed significantly higher NF-L protein expression in group D in comparison with group C on days 7, 14 and 28 after ONC. These findings suggest that there are protective effects of EGCG on RGCs after ONC, indicating EGCG might be a potential therapeutic agent for optic nerve diseases. Copyright 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20471452     DOI: 10.1016/j.neulet.2010.05.020

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  13 in total

Review 1.  Neuroprotective Effect of Natural Products on Peripheral Nerve Degeneration: A Systematic Review.

Authors:  Heitor G Araújo-Filho; Lucindo J Quintans-Júnior; André S Barreto; Jackson R G S Almeida; Rosana S S Barreto; Jullyana S S Quintans
Journal:  Neurochem Res       Date:  2015-12-08       Impact factor: 3.996

2.  (-)-Epigallocatechin-3-gallate modulates spinal cord neuronal degeneration by enhancing growth-associated protein 43, B-cell lymphoma 2, and decreasing B-cell lymphoma 2-associated x protein expression after sciatic nerve crush injury.

Authors:  Waleed M Renno; May Al-Maghrebi; Muddanna S Rao; Haitham Khraishah
Journal:  J Neurotrauma       Date:  2014-11-10       Impact factor: 5.269

Review 3.  Targets of Neuroprotection in Glaucoma.

Authors:  Shaoqing He; Dorota L Stankowska; Dorette Z Ellis; Raghu R Krishnamoorthy; Thomas Yorio
Journal:  J Ocul Pharmacol Ther       Date:  2017-08-18       Impact factor: 2.671

4.  Epigallocatechin-3-gallate attenuates impairment of learning and memory in chronic unpredictable mild stress-treated rats by restoring hippocampal autophagic flux.

Authors:  Hong-Feng Gu; Ya-Xiong Nie; Qiao-Zhen Tong; Ya-Ling Tang; Yang Zeng; Kai-Quan Jing; Xi-Long Zheng; Duan-Fang Liao
Journal:  PLoS One       Date:  2014-11-13       Impact factor: 3.240

Review 5.  Exploring Optic Nerve Axon Regeneration.

Authors:  Hong-Jiang Li; Zhao-Liang Sun; Xi-Tao Yang; Liang Zhu; Dong-Fu Feng
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

6.  (-)-Epigallocatechin-3-gallate protects PC12 cells against corticosterone-induced neurotoxicity via the hedgehog signaling pathway.

Authors:  Sha Feng; Jue Liu; Biao Cheng; Aiping Deng; Hong Zhang
Journal:  Exp Ther Med       Date:  2018-03-08       Impact factor: 2.447

Review 7.  Neuroprotection in Glaucoma: Old and New Promising Treatments.

Authors:  Dario Rusciano; Salvatore Pezzino; Maria Giulia Mutolo; Rossella Giannotti; Aloisa Librando; Nicola Pescosolido
Journal:  Adv Pharmacol Sci       Date:  2017-10-17

8.  Evaluation of Epigallocatechin-3-gallate Modified Collagen Membrane and Concerns on Schwann Cells.

Authors:  Chenyu Chu; Jia Deng; Cong Cao; Yi Man; Yili Qu
Journal:  Biomed Res Int       Date:  2017-08-15       Impact factor: 3.411

9.  Involvement of HDAC6 in ischaemia and reperfusion-induced rat retinal injury.

Authors:  Haihong Yuan; Hui Li; Ping Yu; Qichen Fan; Xuan Zhang; Wei Huang; Junyi Shen; Yongyao Cui; Wei Zhou
Journal:  BMC Ophthalmol       Date:  2018-11-20       Impact factor: 2.209

Review 10.  Rational Basis for Nutraceuticals in the Treatment of Glaucoma.

Authors:  Luigi Antonio Morrone; Laura Rombola; Annagrazia Adornetto; Maria Tiziana Corasaniti; Rossella Russo
Journal:  Curr Neuropharmacol       Date:  2018       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.